Article Text

Download PDFPDF

Pharmacological interventions
Long-acting injectable risperidone as an option in first-episode psychosis
  1. Nancy H Covell
  1. Psychiatry and Mental Health Services and Policy Research, Columbia University and New York State Psychiatric Institute, New York, New York, USA;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

ABSTRACT FROM: Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry 2015;72:822–9.

What is already known on this topic

Appropriate use of antipsychotic medications for people experiencing early episode psychosis is critical for symptom control and for shaping attitudes towards medication as a support to recovery.1 Risperidone is an effective medication in treating early episode psychosis2 and long-acting injectable risperidone may increase early (12-week) adherence rates.3 However, long-acting medications are rarely used following a first episode of schizophrenia4 and the aim of the present study was to compare the clinical efficacy of the long-acting injectable formulation of risperidone with the oral formulation in the early course of schizophrenia.

Methods of the study

Eighty-three people with early episode schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV)) in the Los Angeles area participated between …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.